Matinas BioPharma Holdings
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Matinas BioPharma Holdings's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 66% to $1,096,000. Profit margin reached -2093%. Total operating expenses were $24,862,000.

Profit Margin

Matinas BioPharma Holdings, Inc. (AMEX:MTNB): Profit margin
2014 0 -10.22M
2015 194.49K -9.13M -4697.01%
2016 0 -7.59M
2017 149.68K -15.48M -10345.91%
2018 119.75K -14.08M -11760.39%
2019 90K -15.58M -17316.87%
2020 158.33K -20.59M -13009.9%
2021 33.33K -21.17M -63521%
2022 3.18M -13.01M -408.25%
2023 1.09M -22.94M -2093.25%

MTNB Income Statement (2014 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue
Revenue
1.09M3.18M33.33K158.33K90K119.75K149.68K0194.49K0
Cost of revenue
14.48M16.67M781.49K14.35M11.23M09.01M05.29M5.17M
Gross profit
-13.39M-13.49M-748.15K-14.20M-11.14M119.75K-8.86M0-5.09M-5.17M
Operating exp.
Research and development
14.48M16.67M14.58M14.35M11.23M6.78M9.01M3.94M5.29M5.17M
Selling and marketing
0000000000
Total operating expenses
24.86M11.1M24.76M24.36M19.01M14.76M16.65M8.25M10.10M10.46M
Operating income
-23.76M-24.59M-24.73M-24.20M-18.92M-14.64M-16.50M-8.25M-9.91M-10.46M
Other income (expenses), net
824K3.59M1.45M1.75M1.54M56.55K658.95K658.39K776.09K243.95K
Income before tax
-22.94M-20.99M-23.28M-22.44M-17.37M-14.58M-15.84M-7.59M-9.13M-10.22M
Income tax expense
0-7.98M-2.10M-1.84M-1.78M-506.92K-356.95K-674.90K-756.47K-269.12K
Net income
-22.94M-13.01M-21.17M-20.59M-15.58M-14.08M-15.48M-7.59M-9.13M-10.22M
Earnings per share
Basic EPS
-5.28-0.06-0.1-5.23-0.11-0.14-8.56-0.13-8.87-15.93
Diluted EPS
-5.28-0.06-0.1-5.23-0.11-0.14-8.56-0.13-8.87-15.93
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData source